涌出 发表于 2025-3-21 18:47:20

书目名称Chemosensitivity Testing in Oncology影响因子(影响力)<br>        http://impactfactor.cn/if/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology影响因子(影响力)学科排名<br>        http://impactfactor.cn/ifr/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology网络公开度<br>        http://impactfactor.cn/at/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology网络公开度学科排名<br>        http://impactfactor.cn/atr/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology被引频次<br>        http://impactfactor.cn/tc/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology被引频次学科排名<br>        http://impactfactor.cn/tcr/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology年度引用<br>        http://impactfactor.cn/ii/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology年度引用学科排名<br>        http://impactfactor.cn/iir/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology读者反馈<br>        http://impactfactor.cn/5y/?ISSN=BK0224937<br><br>        <br><br>书目名称Chemosensitivity Testing in Oncology读者反馈学科排名<br>        http://impactfactor.cn/5yr/?ISSN=BK0224937<br><br>        <br><br>

悦耳 发表于 2025-3-21 23:51:20

978-3-642-62412-4Springer-Verlag Berlin Heidelberg 2003

hypertension 发表于 2025-3-22 02:21:25

http://reply.papertrans.cn/23/2250/224937/224937_3.png

庇护 发表于 2025-3-22 05:08:07

http://reply.papertrans.cn/23/2250/224937/224937_4.png

退出可食用 发表于 2025-3-22 12:01:08

http://reply.papertrans.cn/23/2250/224937/224937_5.png

terazosin 发表于 2025-3-22 14:16:42

http://reply.papertrans.cn/23/2250/224937/224937_6.png

terazosin 发表于 2025-3-22 17:18:54

http://reply.papertrans.cn/23/2250/224937/224937_7.png

Engulf 发表于 2025-3-22 23:16:46

http://reply.papertrans.cn/23/2250/224937/224937_8.png

arrogant 发表于 2025-3-23 02:06:27

http://reply.papertrans.cn/23/2250/224937/224937_9.png

Genetics 发表于 2025-3-23 08:11:38

https://doi.org/10.1007/978-1-349-04806-9been achieved by the most effective cytostatics in single-agent therapy leading to a mean 5-year survival rate of less than 5%. More aggressive treatment regimens using multidrug chemotherapy yielded response rates of up to 40% but failed to show a significant benefit in overall survival compared to
页: [1] 2 3 4 5 6 7
查看完整版本: Titlebook: Chemosensitivity Testing in Oncology; Uwe Reinhold,Wolfgang Tilgen Conference proceedings 2003 Springer-Verlag Berlin Heidelberg 2003 brea